Menu
PPD Blog
PPD Blog

Sharing industry knowledge as we
help deliver life-changing therapies.

 

Eligibility criteria in clinical trials - image of patient in hospital bed

Eligibility criteria in clinical trials

Giovanni Monopoli, senior project manager, reflects on what he learned about the eligibility criteria at an American Society of Clinical Oncology (ASCO) conference presentation in 2017.

Read more...
 

Woman with cancer and child - The challenges of immuno-oncology combined clinical development, Part IV

The challenges of immuno-oncology combined clinical development, Part IV

In the final of a four-part series, Jai Balkissoon, vice president of global product development, writes about the challenges in developing immuno-oncology therapies in combination clinical trials.

Read more...
 

Calendar planning holidays - Managing clinical studies through European holidays

Managing clinical studies through European holidays

PPD® Biotech’s Samantha Hadfield, senior director of project management, Helen Dunlop, director of project management, and Rania Laguel, director of project management, provide suggestions on preparing your study for the summer holidays in Europe.

Read more...
 

Cancer patient The challenges of immuno-oncology combined clinical development, Part III

The challenges of immuno-oncology clinical development, Part III

In the third of a four-part series, Jai Balkissoon, vice president of global product development, writes about the challenges in developing immuno-oncology therapies in combination clinical trials.

Read more...
 

Cancer patient with medical professional for the challenges of combination therapies in immuno-oncology clinical development

The challenges of immuno-oncology clinical development, Part II

In the second of a four-part series, Jai Balkissoon, vice president of global product development, writes about the challenges in developing immuno-oncology therapies in combination clinical trials.

Read more...
 

Challenges of immuno-oncology clinical development

The challenges of immuno-oncology clinical development, Part I

In the first of a four-part series, Jai Balkissoon, vice president of global product development, writes about the increase in immuno-oncology therapies.

Read more...
 

Local regulatory affiliates

The future of the local regulatory affiliate: Adjusting to global strategies, processes and expectations

Alistair Davidson, senior director, regulatory affairs, discusses the work of local regulatory affiliates.

Read more...
 

Lungs tuberculosis drug development

PPD’s fight against tuberculosis: Clinical trials with experienced teams

As we recognize World TB (tuberculosis) Day, PPD employees share their experiences working against the disease and their dedication to seek life-changing therapies for TB patients.

Read more...
 

Rare disease day 2018

The personal impact of rare diseases

PPD employees, including a rare disease patient, parent and researcher, share their experiences as we honor Rare Disease Day.

Read more...
 

Benefits of centralized monitoring in clinical trials

Benefits of centralized monitoring in clinical trials

Nicole Stansbury, executive director of adaptive and intelligent monitoring, answers questions about PPD’s clinical trial monitoring strategies.

Read more...
 

Infrastructure Design Is Key to Enhanced Clinical Trials Data Management thumbnail image

Infrastructure design is key to enhanced clinical trials data management

Brent Reed, director of information technology, writes about elements required for managing data for a successful clinical trial.

Read more...
 

Proactivity in a GMP Contract Laboratory thumbnail

Proactivity in a GMP contract laboratory

Chris Forsdyke, executive director, PPD® Laboratories’ GMP lab in Athlone, Ireland, details why proactivity is important even in a regulated laboratory environment.

Read more...
 

Positive changes in the Latin American clinical trial regulatory environment

Positive changes in the Latin American clinical trial regulatory environment

Andres Bayona, executive director in clinical monitoring and regional head of Latin America, and Mercedes Ponce de Leon, senior manager in regulatory affairs, discuss the clinical trial regulatory landscape in Latin America.

Read more...
 

Why use liquid chromatography-mass spectrometry in drug discovery and development?

Why use liquid chromatography-mass spectrometry in drug discovery and development?

Jie Ding, associate director of development and validation at the PPD® Laboratories’ GMP lab, discusses liquid chromatography-mass spectrometry in drug discovery and development.

Read more...
 

First-in-health regulatory changes Kirsten Messmer

Seeking ways to ensure participant safety in first-in-human trials

Kirsten Messmer, Ph.D., R.A.C., principal regulatory affairs specialist, details changes in regulatory guidelines for first-in-human trials.

Read more...
Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2018 Pharmaceutical Product Development, LLC. All rights reserved.